See more : Optima bank S.A. (OPTIMA.AT) Income Statement Analysis – Financial Results
Complete financial analysis of Genovis AB (publ.) (GENO.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genovis AB (publ.), a leading company in the Biotechnology industry within the Healthcare sector.
- Media Investment Optimization, S.A. (MIO.MC) Income Statement Analysis – Financial Results
- audius SE (3IT.DE) Income Statement Analysis – Financial Results
- Salem Erode Investments Limited (SALEM.BO) Income Statement Analysis – Financial Results
- Grupo Ezentis, S.A. (0QIH.L) Income Statement Analysis – Financial Results
- Banco de Sabadell, S.A. (BNDSY) Income Statement Analysis – Financial Results
Genovis AB (publ.) (GENO.ST)
About Genovis AB (publ.)
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company has a collaboration with Waters Corporation. Genovis AB (publ.) was founded in 1999 and is based in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.23M | 102.39M | 93.02M | 61.03M | 60.55M | 34.57M | 22.87M | 18.54M | 13.27M | 8.25M | 8.91M | 6.08M | 2.86M | 1.60M | 986.18K | 379.65K |
| Cost of Revenue | 15.16M | 15.02M | 11.73M | 3.43M | 4.41M | 833.34K | 1.05M | 1.06M | 2.46M | 3.43M | 1.69M | 2.43M | 7.56M | 794.80K | 1.09M | 1.26M |
| Gross Profit | 143.07M | 87.37M | 81.29M | 57.60M | 56.13M | 33.73M | 21.82M | 17.48M | 10.81M | 4.82M | 7.22M | 3.66M | -4.71M | 801.22K | -106.84K | -876.35K |
| Gross Profit Ratio | 90.42% | 85.33% | 87.39% | 94.38% | 92.71% | 97.59% | 95.41% | 94.29% | 81.47% | 58.43% | 81.03% | 60.12% | -164.86% | 50.20% | -10.83% | -230.83% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 21.97M | 18.66M | 17.00M | 13.58M | 14.63M | 26.01M | 21.49M | 12.58M | 11.68M | 9.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.99M | 4.86M | 8.07M |
| SG&A | 88.20M | 68.19M | 21.97M | 18.66M | 17.00M | 13.58M | 14.63M | 26.01M | 21.49M | 12.58M | 11.68M | 9.38M | 0.00 | 5.99M | 4.86M | 8.07M |
| Other Expenses | 651.00K | 73.65M | 38.22M | 34.66M | 25.63M | 19.19M | 392.63K | 12.04M | 14.18M | 13.19M | 11.35M | 10.63M | 9.04M | 6.04M | 7.58M | 16.48M |
| Operating Expenses | 88.85M | 73.65M | 60.18M | 53.32M | 42.63M | 32.76M | 29.65M | 38.05M | 35.68M | 25.77M | 23.03M | 20.01M | 9.04M | 12.03M | 12.45M | 24.54M |
| Cost & Expenses | 104.01M | 88.67M | 71.91M | 56.75M | 47.04M | 33.60M | 30.70M | 39.11M | 38.14M | 29.20M | 24.72M | 22.43M | 16.60M | 12.83M | 13.54M | 25.80M |
| Interest Income | 2.89M | 281.45K | 60.33K | 991.44K | 399.38K | 0.00 | 285.00 | 330.00 | 378.00 | 156.51K | 73.42K | 27.05K | 3.41K | 0.00 | 45.00 | 21.14K |
| Interest Expense | 2.26M | 14.49M | 0.00 | 991.44K | 399.38K | 639.84K | 90.93K | 131.88K | 34.09K | 16.01K | 1.90K | 7.06K | 15.79K | 100.01K | 215.10K | 173.71K |
| Depreciation & Amortization | 9.72M | 6.63M | 5.77M | 5.43M | 3.50M | 3.04M | 1.61M | 1.29M | 1.32M | 1.27M | 873.64K | 1.42M | 1.31M | 1.10M | 1.25M | 6.95M |
| EBITDA | 64.57M | 14.91M | 30.37M | 8.57M | 17.02M | 2.08M | -6.23M | -13.48M | -18.51M | -19.04M | -15.04M | -18.74M | -12.43M | -10.13M | -11.30M | -18.45M |
| EBITDA Ratio | 40.81% | 28.44% | 29.12% | 20.19% | 28.11% | 17.65% | -27.23% | -100.17% | -176.98% | -230.73% | -166.05% | -245.82% | -435.30% | -634.71% | -1,146.02% | -4,859.33% |
| Operating Income | 54.22M | 22.49M | 24.54M | 6.89M | 13.52M | -960.64K | -7.84M | -14.77M | -19.82M | -20.47M | -15.99M | -20.18M | -13.75M | -11.23M | -12.55M | -25.42M |
| Operating Income Ratio | 34.27% | 21.97% | 26.39% | 11.28% | 22.34% | -2.78% | -34.26% | -79.66% | -149.41% | -248.07% | -179.37% | -331.89% | -481.28% | -703.85% | -1,272.96% | -6,695.57% |
| Total Other Income/Expenses | 626.00K | -281.00K | 60.33K | -991.44K | -399.38K | -639.84K | -90.65K | -131.55K | -33.71K | 140.50K | 71.52K | 19.98K | -12.38K | -100.01K | -215.05K | -152.57K |
| Income Before Tax | 54.85M | 8.00M | 24.60M | 2.15M | 9.67M | -1.60M | -7.93M | -14.90M | -19.86M | -20.33M | -15.91M | -20.16M | -13.76M | -11.33M | -12.77M | -25.57M |
| Income Before Tax Ratio | 34.66% | 7.81% | 26.45% | 3.52% | 15.97% | -4.63% | -34.66% | -80.37% | -149.66% | -246.37% | -178.57% | -331.56% | -481.71% | -710.12% | -1,294.77% | -6,735.75% |
| Income Tax Expense | -6.65M | -3.20M | -173.74K | -4.30M | 116.43K | 109.90K | 22.47K | 129.33K | 47.53K | 1.72M | -61.60K | -246.44K | -150.08K | -42.08K | 4.79M | 1.58M |
| Net Income | 61.50M | 11.19M | 24.78M | 6.45M | 9.55M | -1.71M | -7.95M | -15.03M | -19.91M | -22.05M | -15.85M | -19.92M | -13.61M | -11.29M | -17.56M | -27.15M |
| Net Income Ratio | 38.87% | 10.93% | 26.64% | 10.56% | 15.77% | -4.95% | -34.76% | -81.06% | -150.02% | -267.19% | -177.88% | -327.50% | -476.46% | -707.48% | -1,780.43% | -7,151.16% |
| EPS | 0.94 | 0.17 | 0.38 | 0.10 | 0.15 | -0.03 | -0.14 | -0.32 | -0.66 | -0.97 | -0.76 | -1.33 | -1.54 | -2.15 | -7.61 | -17.28 |
| EPS Diluted | 0.94 | 0.17 | 0.38 | 0.10 | 0.15 | -0.03 | -0.14 | -0.32 | -0.66 | -0.96 | -0.76 | -1.33 | -1.54 | -2.15 | -7.61 | -17.28 |
| Weighted Avg Shares Out | 65.47M | 65.47M | 65.47M | 65.09M | 63.10M | 61.94M | 58.69M | 46.59M | 30.06M | 22.81M | 20.88M | 14.98M | 8.81M | 5.25M | 2.31M | 1.57M |
| Weighted Avg Shares Out (Dil) | 65.47M | 65.47M | 65.47M | 65.09M | 63.10M | 61.94M | 58.69M | 46.59M | 30.27M | 23.08M | 20.88M | 14.98M | 8.81M | 5.25M | 2.31M | 1.57M |
Source: https://incomestatements.info
Category: Stock Reports